about
Perspective on lead toxicity, a comparison between the United States and IranTamsulosin for urolithiasis: a review of the recent literature and current controversies.Newly approved antibiotics and antibiotics reserved for resistant infections: Implications for emergency medicine.A review of pharmaceutical labeling for overdose treatment and toxicity data.Trends in pregnancy labeling and data quality for US-approved pharmaceuticals.Trends in paediatric clinical pharmacology data in US pharmaceutical labelling.Elevated compartment pressures from copperhead envenomation successfully treated with antivenin.Best pharmaceuticals for children: how far have we come?Intraperitoneal elemental mercury exposure from a mercury-weighted bougie.High dose insulin therapy, an evidence based approach to beta blocker/calcium channel blocker toxicity.A retrospective cross-sectional study of patients treated in US EDs and ambulatory care clinics with sexually transmitted infections from 2001 to 2010.Updates in the general approach to the pediatric poisoned patient.Critical drug shortages: implications for emergency medicine.Trends in opioid analgesic use for headaches in US emergency departments.Magnesium depletion in patients treated with therapeutic hypothermia after cardiac arrest.U.S. drug shortages for medications used in adult critical care (2001-2016).Trends in Emergency Department Resource Utilization for Poisoning-Related Visits, 2003-2011.Accuracy of rapid sequence intubation medication dosing in obese patients intubated in the ED.The Prescription Opioid Epidemic: Social Media Responses to the Residents' Perspective Article.Alcohol-Related Visits to US Emergency Departments, 2001-2011.Initiation of an Inhaled Corticosteroid During a Pediatric Emergency Visit for Asthma: A Randomized Clinical Trial.Emerging trends in antibiotic resistance: Implications for emergency medicine.Trends in prescription opioid use in pediatric emergency department patients.Longitudinal Trends in U.S. Drug Shortages for Medications Used in Emergency Departments (2001-2014).Benzodiazepine Prescribing in Older Adults in U.S. Ambulatory Clinics and Emergency Departments (2001-10).Drug shortages: Implications for medical toxicology.Antibacterial drug shortages from 2001 to 2013: implications for clinical practice.U.S. vaccine and immune globulin product shortages, 2001-15.In Response: The Contribution of the Emergency Department to Opioid Pain Reliever Misuse and Diversion: A Critical Review.Rising rates of proton pump inhibitor prescribing in US emergency departments.Trends in Opioid Analgesic Use in Encounters Involving Physician Trainees in U.S. Emergency Departments.Rising opioid prescribing in adult U.S. emergency department visits: 2001-2010.Effect of cough and cold medication restriction and label changes on pediatric ingestions reported to United States poison centers.Impact of the CYP2C19*17 polymorphism on the pharmacokinetics and pharmacodynamics of proton pump inhibitors.Promoting therapeutic equity in pregnancy.Correction to: ACMT Position Statement: Addressing the Rising Cost of Prescription Antidotes.Advances in Diabetes Pharmacotherapy: An Update for the Emergency Provider.ACMT Position Statement: Addressing the Rising Cost of Prescription Antidotes.Segway® Personal Transporter-Related Injuries: A Systematic Literature Review and Implications for Acute and Emergency Care.Emergency department approach to QTc prolongation.
P50
Q28393598-B8A28FFF-AA7D-41E8-AFD6-EDBC256600CBQ30393059-C4C1ADD8-4CA2-498A-9B4E-5BB294D4EF7BQ30396854-634F7232-A203-40A0-B074-62751C68D17EQ30584220-F6673E8E-F83F-4C64-81ED-66D5E6D730E4Q30829996-A980A5E3-D10A-450F-821A-66EC636007F5Q30838802-DA559170-ADA2-4A6E-AE96-6FE0E29E2067Q33409250-C49A7D48-116D-45FE-8667-563E40CBDC7EQ33561243-25FB845D-F63C-4341-AD89-0EB98EE1A429Q37165389-C7935E32-5A44-45F2-BA41-DA2D6D066621Q37701108-482DB588-470C-40E0-B178-7965EA2C4A87Q37836088-C196DAAE-A07E-4A3B-80AC-B855371ACC03Q38149285-16A42FA0-DF5F-4CE3-A149-6D13D206786BQ38231341-A9AAE2E1-E01A-4DB2-9A1F-378F0E244F7AQ38236909-BD7DE599-A5A8-4C05-B28A-95E49E94F682Q38253466-D236D46D-AF1C-4B70-9EFC-EEA0484C132EQ38722115-0ADEDE48-6FAB-4320-845D-E36866080C03Q38876339-55D9F501-B433-4821-95DD-303F36D70757Q38977921-F59F8D27-EE31-47EE-AD7A-8D2A7152F1D7Q38985222-E122A4C1-9EB4-432E-9269-1D87BB49339CQ39044908-764BEEBE-BE0C-4A5C-B751-604625F4E5CDQ39163293-31D18F22-B11E-4803-86E8-B8ECEB194908Q39182633-CA555622-68C7-4A19-A6C9-0952A5543B08Q39209786-33B0E985-F9B2-4581-8DFE-D374F7179096Q40160222-38DB0C73-9121-4E98-8317-E7DEF30C885EQ40490191-2941C01D-4F27-44F6-B442-0F41A33EEFB8Q40964486-E0FED2FA-B6F4-4053-AC83-914DE13C2B35Q41019741-3E260DC9-0F18-4853-87D3-C1F9B267E3C1Q41925961-F8539410-4D30-4F2F-9893-427656D80EE5Q43061796-785C9628-8FEA-4909-BC39-05732C71EB9AQ43826184-CD47C17C-177E-48D9-A5B5-298D1B024F33Q44336540-DADD57A7-EFDE-4A17-8386-3952851870F1Q44343892-71A0F280-E749-4A1C-A6DE-A7041F84200AQ44488133-D4946B76-3C6F-4EC0-9CCB-248A17F0F067Q45817540-84F0E830-35A5-44C6-ACAC-5AF3BCD76C66Q46262917-9A1EAC89-C303-4768-801C-06BFB1896F4CQ48502780-266D7B10-8010-4C43-90C1-239C0F011E6CQ49540636-91CE046D-F7BE-4240-84D0-B1770A0661D0Q49559539-84AD6A77-9267-499C-B2D3-26AE422F7F29Q50102379-5A24462F-FED6-4B72-838F-7C0ECF583245Q50268612-2EBF4209-0983-4687-9C88-D95F8E185817
P50
description
researcher (ORCID 0000-0001-8362-2013)
@en
name
Maryann Mazer-Amirshahi
@en
type
label
Maryann Mazer-Amirshahi
@en
prefLabel
Maryann Mazer-Amirshahi
@en
P31
P496
0000-0001-8362-2013